Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial

@article{Schmidt2005MethylxanthineTF,
  title={Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial},
  author={Barbara Schmidt},
  journal={Neonatology},
  year={2005},
  volume={88},
  pages={208 - 213}
}
Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation. Recent research has raised concerns about the safety of methylxanthines in very preterm infants. Possible adverse effects include poor growth, worsening of hypoxic-ischemic brain damage and abnormal childhood behavior. Over 2,000 infants with birth weights 500–1,250 g have been randomized in the international placebo-controlled Caffeine for Apnea of Prematurity (CAP) trial to examine the long-term… Expand
Long-term effects of caffeine therapy for apnea of prematurity.
TLDR
Caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability at 18 to 21 months in infants with very low birth weight. Expand
Caffeine therapy for apnea of prematurity.
TLDR
Caffeine therapy for apnea of prematurity reduces the rate of bronchopulmonary dysplasia in infants with very low birth weight and reduced weight gain temporarily. Expand
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
TLDR
Neonatal caffeine therapy was no longer associated with a significantly improved rate of survival without disability in children with very low birth weights who were assessed at 5 years. Expand
Ca # eine therapy for apnoea of prematurity in very low-birthweight infants
Ca"eine and other methylxanthines have been used to treat apnoea of prematurity for over 30 years. However, until recently, experimental evidence of the potential harm and lack of rigorous evaluationExpand
Caffeine in preterm infants: where are we in 2020?
TLDR
It is speculated that with increased understanding of caffeine and its metabolism, a more refined respiratory management of preterm infants is feasible, leading to an overall improvement in patient outcome. Expand
Current management of apnea in premature infants: is caffeine the magic bullet?
TLDR
The management of the infant with apnea episodes should start by identifying and correcting known conditions that can increase their incidence, including metabolic abnormalities such as hypoglycemia, hypocalcemia and metabolic alkalosis, anemia and arterial hypotension, and any condition that increases the work of breathing. Expand
Caffeine therapy for apnoea of prematurity: Pharmacological treatment
TLDR
A review of the pharmacokineƟ cs of caff eine and its cellular eff ect on the physiology of newborns with apnoea and some intriguing possibiliƟ es, such as the protecƟ ve on the brain and lungs are reported. Expand
Erythropoietin and caffeine exert similar protective impact against neonatal intermittent hypoxia: Apnea of prematurity and sex dimorphism
TLDR
Neonatal IH and the treatments tested to prevent its respiratory consequences are sex-specific and are relevant to understanding better the AoP disorder and for proposing Epo as a new therapeutical tool. Expand
Prevention and treatment of bronchopulmonary dysplasia: current status and future prospects
TLDR
Owing to potential short- and long-term effects, postnatal corticosteroids should be restricted to the most severe manifestations of BPD. Expand
Nonventilatory Strategies for Prevention and Treatment of Bronchopulmonary Dysplasia – What Is the Evidence?
TLDR
The evidence for a number of mainly drug-related strategies to prevent or treat bronchopulmonary dysplasia (BPD), including oxygen supplementation, anti-inflammatory drugs, and antioxidants have not been proven effective yet. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 66 REFERENCES
Methylxanthine treatment for apnea in preterm infants.
TLDR
Methylxanthines are effective in reducing the number of apneic attacks and the use of mechanical ventilation in the two to seven days after starting treatment, and caffeine would be the preferred drug. Expand
Historical Perspectives: Use of Methylxanthines in the Management of Apneic Attacks in the Newborn
TLDR
During 1969, a preterm baby in the special care unit developed numerous apneic attacks that lasted 30 seconds or longer and were associated with periods of bradycardia and hypoxia, and died 18 days after birth. Expand
Controversies surrounding xanthine therapy.
TLDR
An international controlled clinical trial is underway to examine the long-term efficacy and safety of methylxanthine therapy in very low birth weight babies. Expand
Effect of Caffeine on Oxygen Consumption and Metabolic Rate in Very Low Birth Weight Infants With Idiopathic Apnea
TLDR
Long-term administration of caffeine in preterm infants is associated with an increase in oxygen consumption and with a reduction of weight gain, which may have implications for clinical practice as nutritional regimens need to be adjusted during this therapy. Expand
Metabolic and respiratory effects of theophylline in the preterm infant
TLDR
After theophylline treatment, preterm infants had faster respiration, lower transcutaneous CO2, and improved static respiratory compliance without increased physical activity, which could be detrimental to the growth of the preterm infant. Expand
Oxygen consumption in apneic premature infants after low‐dose theophylline
TLDR
This dose of theophylline is effective in idiopathic apnea of prematurity and acts as a metabolic stimulant in the premature infant and increases in . Expand
Preterm outcomes research: a critical component of neonatal intensive care.
  • M. Allen
  • Medicine
  • Mental retardation and developmental disabilities research reviews
  • 2002
TLDR
Ongoing longterm preterm neurodevelopmental studies, analysis of changes in outcomes over time and among centers, and evaluation of the longterm safety, efficacy and effectiveness of many perinatal and neonatal management strategies and proposed neuroprotective agents are all necessary for further medical and technological advances in neonatal intensive care. Expand
Effect of aminophylline on respiratory center activity and metabolic rate in premature infants with idiopathic apnea.
TLDR
Findings support the hypothesis that apnea in premature infants is related to an immature respiratory center characterized by a decreased output, and Aminophylline probably increases respiratory center output by lowering the threshold of the central chemorecepter to CO2. Expand
Cognitive function in preterm infants: no simple answers.
TLDR
Findings suggest some reasons for optimism regarding the cognitive outcome in VLBW children, but also highlights several potentially problematic issues found in follow-up studies. Expand
Outcome at 5–6 years of prematurely born children who received morphine as neonates
TLDR
Exposure to morphine in the neonatal period to facilitate mechanical ventilation does not seem to have any adverse effects on intelligence, motor function, or behaviour when these children are assessed at 5–6 years of age. Expand
...
1
2
3
4
5
...